129 related articles for article (PubMed ID: 2563962)
1. Pharmacokinetics of esmolol and ASL-8123 in renal failure.
Flaherty JF; Wong B; La Follette G; Warnock DG; Hulse JD; Gambertoglio JG
Clin Pharmacol Ther; 1989 Mar; 45(3):321-7. PubMed ID: 2563962
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of esmolol in children.
Wiest DB; Trippel DL; Gillette PC; Garner SS
Clin Pharmacol Ther; 1991 Jun; 49(6):618-23. PubMed ID: 1676357
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
[TBL] [Abstract][Full Text] [Related]
4. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias.
Adamson PC; Rhodes LA; Saul JP; Dick M; Epstein MR; Moate P; Boston R; Schreiner MS
Pediatr Cardiol; 2006; 27(4):420-7. PubMed ID: 16835806
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of esmolol in hepatic disease.
Buchi KN; Rollins DE; Tolman KG; Achari R; Drissel D; Hulse JD
J Clin Pharmacol; 1987 Nov; 27(11):880-4. PubMed ID: 3323260
[TBL] [Abstract][Full Text] [Related]
7. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
[TBL] [Abstract][Full Text] [Related]
8. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
[TBL] [Abstract][Full Text] [Related]
9. Esmolol-digoxin drug interaction.
Lowenthal DT; Porter RS; Achari R; Turlapaty P; Laddu AR; Matier WL
J Clin Pharmacol; 1987 Aug; 27(8):561-6. PubMed ID: 2888792
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.
Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
J Cardiovasc Pharmacol; 2018 Mar; 71(3):137-146. PubMed ID: 29112591
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.
Sum CY; Yacobi A; Kartzinel R; Stampfli H; Davis CS; Lai CM
Clin Pharmacol Ther; 1983 Oct; 34(4):427-34. PubMed ID: 6617063
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Swartz RD; Starmann B; Horvath AM; Olson SC; Posvar EL
J Clin Pharmacol; 1990 Dec; 30(12):1136-41. PubMed ID: 2273086
[TBL] [Abstract][Full Text] [Related]
14. Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure.
Donnelly PK; Burwell N; McBurney A; Ward JW; Walls J; Watkin EM
Br J Radiol; 1992 Dec; 65(780):1108-13. PubMed ID: 1286420
[TBL] [Abstract][Full Text] [Related]
15. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D
Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
[TBL] [Abstract][Full Text] [Related]
16. Gas chromatographic-mass spectrometric assay for the ultra-short-acting beta-blocker esmolol.
Sum CY; Yacobi A
J Pharm Sci; 1984 Aug; 73(8):1177-9. PubMed ID: 6149299
[TBL] [Abstract][Full Text] [Related]
17. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance.
Payton CD; Fox JG; Pauleau NF; Boulton-Jones JM; Ioannides C; Johnston A; Thomas P
Eur Heart J; 1987 Dec; 8 Suppl M():15-22. PubMed ID: 2897297
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
Kowalsky SF; Echols M; Schwartz MT; Bailie GR; McCormick E
Clin Nephrol; 1993 Jan; 39(1):53-8. PubMed ID: 8428409
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
Bohjanen PR; Johnson MD; Szczech LA; Wray DW; Petros WP; Miller CR; Hicks CB
Antimicrob Agents Chemother; 2002 Aug; 46(8):2387-92. PubMed ID: 12121909
[TBL] [Abstract][Full Text] [Related]
20. Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.
Veys N; Lameire N; Malerczyk V; Lehr KH; Rosenkranz B; Ringoir S
Clin Pharmacol Ther; 1993 Oct; 54(4):395-401. PubMed ID: 8222482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
